Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Citius Aims To Use Prior Experience With CTCL Drug To Its Commercial Advantage

Executive Summary

The company announced positive data for I/Ontak, a reformulated version of the cutaneous T-cell lymphoma drug Ontak and aims to submit for approval later in 2022.

You may also be interested in...



Finance Watch: Lexeo Launches 20th US Biopharma IPO In 2023

Public Company Edition: Lexeo raised $100m to advance its genetic medicines. Also, Blue Owl Capital acquired funds managed by Cowen Healthcare Investments, gaining about $1bn in life science assets, BMS priced $4.5bn in notes to fund its Mirati purchase and Viridian raised $185m in a private placement.

Keeping Track: Orphans Headline FDA Approvals; Gene Therapies Stand Out Among Submissions

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

Sales Of BioMarin’s Hemophilia Gene Therapy Move At Glacial Pace

Analysts had forecast Q4 Roctavian sales of $5m-$6m, but they came in shy of $3m, and uptake has not yet come to reflect apparent demand.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC146189

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel